Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,cash,totalCurrentLiabilities,totalCurrentAssets,netReceivables,accountsPayable,otherCurrentLiab,changeToLiabilities,changeToOperatingActivities,totalCashFromOperatingActivities,changeInCash,totalCashFromFinancingActivities,issuanceOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 12, 2016) 4","Short Ratio (May 12, 2016) 4","Short % of Float (May 12, 2016) 4","Short % of Shares Outstanding (May 12, 2016) 4","Shares Short (prior month Apr 14, 2016) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,ENZN,6865000.0,74214600,,,13000,,11000,370000,381000,11000,11000,,,,,,2000,381000,370000,0,2000,,11000,-495000,77500000.0,461000.0,6865000.0,48292000.0,742000.0,40000.0,-71377000.0,48187000.0,461000.0,48292000.0,65000.0,329000.0,,0.0,34000.0,45000.0,45000.0,,,,47831000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,ENZON PHARMACEUTICALS INC,False,False,PNK,0.3967,1630507054,0.06654999,0.376,0.3967,0.3399,24766,REGULAR,0,4,20.1575,0.3399 - 0.3967,0.33015,0.38,1.41,30,2,finmb_269599,"Enzon Pharmaceuticals, Inc.",Other OTC,USD,68217,41283,0.37669998,18.835,0.02 - 0.85,-0.45330003,-0.53329414,0.02,0.85,1571097600,1550800800,1550800800,1550800800,-0.035,0.093,0.49166667,-0.09496668,-0.19315256,0.60507244,-0.20837244,-0.34437603,29440932,4.265591,15,America/New_York,EDT,-14400000,0.34,,,0.85,0.02,0.4917,0.6051,68.22k,41.28k,74.21M,,30.11M,10.85%,54.66%,259.38k,1.71,0.68%,0.59%,298.38k,,,,,,0.00%,"Oct 14, 2019","Sep 29, 2019",1:1,"Sep 28, 2017","Dec 30, 2020","Mar 30, 2021",-245.48%,-244.55%,-2.42%,-3.95%,431k,0.01,"18,950.00%",52k,,-2.02M,-0.0350,,48.19M,0.65,,,104.75,0.09,-33k,366.25k,Value,07016,Healthcare,"Enzon Pharmaceuticals, Inc., together with its subsidiaries, licenses drug products. Its marketed drug products include PegIntron and Sylatron. The company was incorporated in 1981 and is headquartered in Cranford, New Jersey.",Cranford,732 980 4500,NJ,1609372800,United States,http://www.enzon.com,86400,20 Commerce Drive,Biotechnology,Suite 135
t-1,ENZN,7360000.0,74214600,,,-421000,,-426000,456000,34000,-422000,-422000,,,,,,5000,34000,456000,0,1000,,-426000,-886000,78006000.0,412000.0,7360000.0,48232000.0,742000.0,59000.0,-71388000.0,48142000.0,412000.0,48232000.0,31000.0,302000.0,18000.0,948000.0,-1067000.0,-545000.0,42831000.0,43376000.0,43600000.0,-224000.0,47820000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,ENZON PHARMACEUTICALS INC,False,False,PNK,0.3967,1630507054,0.06654999,0.376,0.3967,0.3399,24766,REGULAR,0,4,20.1575,0.3399 - 0.3967,0.33015,0.38,1.41,30,2,finmb_269599,"Enzon Pharmaceuticals, Inc.",Other OTC,USD,68217,41283,0.37669998,18.835,0.02 - 0.85,-0.45330003,-0.53329414,0.02,0.85,1571097600,1550800800,1550800800,1550800800,-0.035,0.093,0.49166667,-0.09496668,-0.19315256,0.60507244,-0.20837244,-0.34437603,29440932,4.265591,15,America/New_York,EDT,-14400000,0.34,,,0.85,0.02,0.4917,0.6051,68.22k,41.28k,74.21M,,30.11M,10.85%,54.66%,259.38k,1.71,0.68%,0.59%,298.38k,,,,,,0.00%,"Oct 14, 2019","Sep 29, 2019",1:1,"Sep 28, 2017","Dec 30, 2020","Mar 30, 2021",-245.48%,-244.55%,-2.42%,-3.95%,431k,0.01,"18,950.00%",52k,,-2.02M,-0.0350,,48.19M,0.65,,,104.75,0.09,-33k,366.25k,Value,07016,Healthcare,"Enzon Pharmaceuticals, Inc., together with its subsidiaries, licenses drug products. Its marketed drug products include PegIntron and Sylatron. The company was incorporated in 1981 and is headquartered in Cranford, New Jersey.",Cranford,732 980 4500,NJ,1609372800,United States,http://www.enzon.com,86400,20 Commerce Drive,Biotechnology,Suite 135
t-2,ENZN,5170000.0,74214600,,,-407000,,-407000,415000,8000,-407000,-407000,,,,,,0,8000,415000,0,0,,-407000,-407000,75690000.0,654000.0,5170000.0,5824000.0,442000.0,513000.0,-70962000.0,5311000.0,654000.0,5824000.0,,306000.0,,0.0,109000.0,-298000.0,-598000.0,-300000.0,43600000.0,-300000.0,5170000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,ENZON PHARMACEUTICALS INC,False,False,PNK,0.3967,1630507054,0.06654999,0.376,0.3967,0.3399,24766,REGULAR,0,4,20.1575,0.3399 - 0.3967,0.33015,0.38,1.41,30,2,finmb_269599,"Enzon Pharmaceuticals, Inc.",Other OTC,USD,68217,41283,0.37669998,18.835,0.02 - 0.85,-0.45330003,-0.53329414,0.02,0.85,1571097600,1550800800,1550800800,1550800800,-0.035,0.093,0.49166667,-0.09496668,-0.19315256,0.60507244,-0.20837244,-0.34437603,29440932,4.265591,15,America/New_York,EDT,-14400000,0.34,,,0.85,0.02,0.4917,0.6051,68.22k,41.28k,74.21M,,30.11M,10.85%,54.66%,259.38k,1.71,0.68%,0.59%,298.38k,,,,,,0.00%,"Oct 14, 2019","Sep 29, 2019",1:1,"Sep 28, 2017","Dec 30, 2020","Mar 30, 2021",-245.48%,-244.55%,-2.42%,-3.95%,431k,0.01,"18,950.00%",52k,,-2.02M,-0.0350,,48.19M,0.65,,,104.75,0.09,-33k,366.25k,Value,07016,Healthcare,"Enzon Pharmaceuticals, Inc., together with its subsidiaries, licenses drug products. Its marketed drug products include PegIntron and Sylatron. The company was incorporated in 1981 and is headquartered in Cranford, New Jersey.",Cranford,732 980 4500,NJ,1609372800,United States,http://www.enzon.com,86400,20 Commerce Drive,Biotechnology,Suite 135
t-3,ENZN,5577000.0,74214600,,,-236000,,-236000,244000,8000,-236000,-236000,,,,,,0,8000,244000,0,0,,-236000,-236000,75690000.0,427000.0,5577000.0,6004000.0,442000.0,95000.0,-70555000.0,5909000.0,427000.0,6004000.0,,314000.0,,0.0,1001000.0,765000.0,765000.0,-300000.0,43600000.0,-300000.0,5577000.0,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,ENZON PHARMACEUTICALS INC,False,False,PNK,0.3967,1630507054,0.06654999,0.376,0.3967,0.3399,24766,REGULAR,0,4,20.1575,0.3399 - 0.3967,0.33015,0.38,1.41,30,2,finmb_269599,"Enzon Pharmaceuticals, Inc.",Other OTC,USD,68217,41283,0.37669998,18.835,0.02 - 0.85,-0.45330003,-0.53329414,0.02,0.85,1571097600,1550800800,1550800800,1550800800,-0.035,0.093,0.49166667,-0.09496668,-0.19315256,0.60507244,-0.20837244,-0.34437603,29440932,4.265591,15,America/New_York,EDT,-14400000,0.34,,,0.85,0.02,0.4917,0.6051,68.22k,41.28k,74.21M,,30.11M,10.85%,54.66%,259.38k,1.71,0.68%,0.59%,298.38k,,,,,,0.00%,"Oct 14, 2019","Sep 29, 2019",1:1,"Sep 28, 2017","Dec 30, 2020","Mar 30, 2021",-245.48%,-244.55%,-2.42%,-3.95%,431k,0.01,"18,950.00%",52k,,-2.02M,-0.0350,,48.19M,0.65,,,104.75,0.09,-33k,366.25k,Value,07016,Healthcare,"Enzon Pharmaceuticals, Inc., together with its subsidiaries, licenses drug products. Its marketed drug products include PegIntron and Sylatron. The company was incorporated in 1981 and is headquartered in Cranford, New Jersey.",Cranford,732 980 4500,NJ,1609372800,United States,http://www.enzon.com,86400,20 Commerce Drive,Biotechnology,Suite 135
